|
| Status |
Public on Jul 30, 2012 |
| Title |
Chemosensitization of DLBCL cells in vitro and in vivo by demethylating nucleoside analogues [gene expression] |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by array
|
| Summary |
Silencing of genes that suppress the malignant phenotype by DNA methylation spurred an interest in the clinical use of epigenetic reprogramming agents. Single therapy is unlikely to be curative in the context of a heterogeneous disease such as Diffuse Large B cell Lymphomas (DLBCL). The combination of DNA demethylating drugs could increase the chance to respond to classical and new treatments. We found that DLBCL cell lines respond heterogeneously to DNA demethylating agents. In sensitive cell lines, 5-aza-2’-deoxycytidine induced a genomic signature similar to that of doxorubicin, the most important drug of the combinatorial chemotherapy regimen for DLBCL treatment. Accordingly, the combination of 5-aza-2’-deoxycytidine and doxorubicin proved to be synergistic in cell killing in vitro and in vivo for DLBCL cell lines individually responsive to these drugs. In doxorubicin resistant cell lines, long-term exposure to low-dose of 5-aza-2’-deoxycytidine induces DNA demethylation and subsequent doxorubicin sensitization in vitro and in vivo. This later effect correlates with SMAD1 demethylation. SMAD1 is epigenetically silenced in doxorubicin-resistant DLBCL cells and DLBCL patients with poor prognostic. In addition, we found that DNA demethylating agents can sensitize primary DLBCL cells to doxorubicin. Primary cells obtained from a DLBCL patient treated with 5-azacytidine shows SMAD1 demethylation and ex vivo sensitization to multiple drugs. Therefore, DNA demethylating drugs can reprogram otherwise resistant DLBCL cells to respond to chemotherapy agents without increasing the toxicity to normal tissues. Our data also indicate that DNA methylation and consequent suppression of SMAD1 expression represent a previously undescribed molecular mechanism of chemoresistance in DLBCL that can be further exploit for therapy.
|
| |
|
| Overall design |
A microarray study using double-stranded cDNA from different DLBCL cell lines before any treatment. Two biological replicates by cell line. The gene expression will be used to find gene expression signatures between sensitive and resistant cell lines to chemotherapeutics.
|
| |
|
| Contributor(s) |
Cerchietti L, Yang S |
| Citation(s) |
23955273 |
| |
| Submission date |
Apr 20, 2011 |
| Last update date |
Oct 21, 2013 |
| Contact name |
thomas clozel |
| E-mail(s) |
thc2014@med.cornell.edu
|
| Phone |
212-746-7622
|
| Fax |
212-746-8866
|
| Organization name |
Weill Cornell Medical College
|
| Department |
Hematology-Oncology
|
| Lab |
Ari Melnick
|
| Street address |
1300 York Avenue
|
| City |
New-York |
| State/province |
NY |
| ZIP/Postal code |
10023 |
| Country |
USA |
| |
|
| Platforms (1) |
|
| Samples (30)
|
|
| This SubSeries is part of SuperSeries: |
| GSE31104 |
Chemosensitization of DLBCL cells in vitro and in vivo by demethylating nucleoside analogues |
|
| Relations |
| BioProject |
PRJNA153947 |
Less...
More...